Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - leucovorin calcium (unii: rpr1r4c0p4) (leucovorin - unii:q573i9dvlp) - leucovorin calcium, usp rescue is indicated after high dose methotrexate therapy in osteosarcoma. leucovorin calcium, usp is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. leucovorin calcium, usp is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. leucovorin calcium, usp is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. leucovorin should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form. leucovorin is improper therapy for pernicious anemia and other megaloblastic anemias secondary to the lack of vitamin b12 . a hematologic remission may occur while neurologic manifestations continue to progress.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risk of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine is contraindicated in patients with idiopath

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - milrinone lactate (unii: 9k8xr81mo8) (milrinone - unii:ju9yax04c7) - milrinone lactate 10 mg in 10 ml - milrinone lactate injection, usp and milrinone lactate in 5% dextrose injection are indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. the facility for immediate treatment of potential cardiac events, which may include life threatening ventricular arrhythmias, must be available. the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. there is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. milrinone lactate injection, usp and milrinone lactate in 5% dextrose injection are contraindicated in patients who are hypersensitive to it.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - testosterone cypionate (unii: m0xw1ubi14) (testosterone - unii:3xmk78s47o) - testosterone cypionate 200 mg in 1 ml - testosterone cypionate injection, usp is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. - primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. - hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (lhrh) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. safety and efficacy of testosterone cypionate in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. - known hypersensitivity to the drug - males with carcinoma of the breast - males with known or suspected carcinoma of the prostate gland - women who are pregnant (see precautions, pregnancy ) - patients with serious cardiac, hepatic or renal disease (see warnings ) testosterone cypionate injection contains testoster

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - glycopyrrolate 0.2 mg in 1 ml - glycopyrrolate injection, usp is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. when indicated, glycopyrrolate injection, usp may be used intraoperatively to counteract surgically or drug‑induced or vagal reflexes associated arrhythmias. glycopyrrolate protects against the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing muscle relaxants. for use in adults as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated. known hypersensitivity to glycopyrrolate or any of its inactive ingredients. in addition, in the management of peptic ulcer patients, because

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - terbutaline sulfate (unii: 576pu70y8e) (terbutaline - unii:n8onu3l3pg) - terbutaline sulfate 1 mg in 1 ml - terbutaline sulfate injection, usp is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema. 1. prolonged tocolysis terbutaline sulfate has not been approved and should not be used for prolonged tocolysis (beyond 48-72 hours). in particular, terbutaline sulfate should not be used for maintenance tocolysis in the outpatient or home setting (see boxed warning: prolonged tocolysis ). 2. hypersensitivity terbutaline sulfate injection is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - dopamine hydrochloride (unii: 7l3e358n9l) (dopamine - unii:vtd58h1z2x) - dopamine hydrochloride 40 mg in 1 ml - dopamine hydrochloride, usp is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. patients most likely to respond adequately to dopamine hydrochloride, usp are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine hydrochloride, usp, the better the prognosis. where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine hydrochloride, usp. poor perfusion of vital organs – urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be mo

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - terbutaline sulfate (unii: 576pu70y8e) (terbutaline - unii:n8onu3l3pg) - terbutaline sulfate injection, usp is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema. 1. prolonged tocolysis terbutaline sulfate has not been approved and should not be used for prolonged tocolysis (beyond 48-72 hours). in particular, terbutaline sulfate should not be used for maintenance tocolysis in the outpatient or home setting (see boxed warning: prolonged tocolysis ). 2. hypersensitivity terbutaline sulfate injection is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - testosterone cypionate (unii: m0xw1ubi14) (testosterone - unii:3xmk78s47o) - testosterone cypionate injection, usp is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. - primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. - hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (lhrh) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. safety and efficacy of testosterone cypionate in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. - known hypersensitivity to the drug - males with carcinoma of the breast - males with known or suspected carcinoma of the prostate gland - women who are pregnant (see precautions, pregnancy ) - patients with serious cardiac, hepatic or renal disease (see warnings ) testosterone cypionate injection contains testoster

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - doxercalciferol (unii: 3diz9lf5y9) (doxercalciferol - unii:3diz9lf5y9) - doxercalciferol 2 ug in 1 ml - doxercalciferol injection is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. doxercalciferol injection should not be given to patients with a tendency towards hypercalcemia or current evidence of vitamin d toxicity. doxercalciferol injection is contraindicated in patients with previous hypersensitivity to doxercalciferol or any of its ingredients (see warnings and adverse reactions ).